Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France (PARROTFISH)

G

Galapagos

Status

Active, not recruiting

Conditions

Rheumatoid Arthritis

Treatments

Drug: Filgotinib

Study type

Observational

Funder types

Industry

Identifiers

NCT05323591
GLPG0634-CL-424
49028 (Other Identifier)

Details and patient eligibility

About

An observational study to describe the effectiveness, safety, and patient-reported outcomes (PROs) in participants with moderate to severe active rheumatoid arthritis (RA) in France receiving filgotinib in real-world setting.

Enrollment

155 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants aged ≥18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local treatment practices and product label for the first time.
  • Female participants of childbearing potential must agree to use contraception while taking filgotinib as per product label.
  • Participants must be willing and able to use an electronic device to complete the study PROs.
  • Participant must sign and date the Informed Consent Form (ICF) before enrollment into the study.

Exclusion criteria

  • Participation in any interventional or non-interventional study without prior approval from the Medical Lead. This does not preclude inclusion of participants enrolled to national registries.
  • Female participant is pregnant or intending to become pregnant while taking filgotinib.

Trial design

155 participants in 1 patient group

Filgotinib
Description:
Participants will receive treatment for moderate to severe active RA with at least one dose of filgotinib in accordance with the product label.
Treatment:
Drug: Filgotinib

Trial contacts and locations

19

Loading...

Central trial contact

Galapagos Medical Information

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems